Interestingly, RUNX3 inactivation in KRAS driven lung adenocarcinoma has been shown to accelerate malignant progression [36] and it will be of interest to test, whether RUNX interferes with YAP-FOS/AP1 co-operation in mediating EMT and malignant tumor progression. Here, RUNX3 is linked to lung adenocarcinoma.